TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Low Glycemic Index Diets to Improve Glycemic Control and Cardiovascular Disease in Type 2 Diabetics
Brief Summary: A low glycemic index diet may improve glycemic control and reduce plaque buildup in arteries of those with type 2 diabetes. Subjects will be randomly assigned to receive dietary advice on either a low glycemic index diet, or a high cereal fibre diet, for three years.


Options:
A: Arm Label: low glycemic index, diabetic diet; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: low glycemic diet instruction | Arm Label: high cereal fibre, diabetic diet; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: high cereal fibre diet instruction | Intervention Type: DIETARY_SUPPLEMENT; Name: low glycemic diet instruction; Assigned to Arm(s): low glycemic index, diabetic diet | Intervention Type: DIETARY_SUPPLEMENT; Name: high cereal fibre diet instruction; Assigned to Arm(s): high cereal fibre, diabetic diet
B: Intervention Type: BEHAVIORAL; Name: high protein & low glycemic index diets; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Intervention Type: BEHAVIORAL; Name: High or low Glycemic Index and high or low Protein Diet; Assigned to Arm(s): 1, 2, 3, 4, 5
D: Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle counseling | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle counseling; Assigned to Arm(s): Lifestyle counseling

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double Blinded, Multicentre Phase II Study to Assess the Efficacy of Olaparib (AZD2281, KU-0059436) in Combination With Paclitaxel Versus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy
Brief Summary: To assess the efficacy of olaparib when given in combination with paclitaxel compared with paclitaxel alone as defined by progression-free survival (PFS), in all patients with recurrent and metastatic gastric cancer who progress following first-line therapy.


Options:
A: Arm Label: Arm A: Lapatinib; Type: EXPERIMENTAL; Interventions: Drug: Lapatinib | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Lapatinib plus capecitabine | Intervention Type: DRUG; Name: Lapatinib; Assigned to Arm(s): Arm A: Lapatinib | Intervention Type: DRUG; Name: Lapatinib plus capecitabine; Assigned to Arm(s): Arm B
B: Arm Label: Arm A (ECF + cetuximab); Type: EXPERIMENTAL; Interventions: Biological: cetuximab, Drug: ECF | Arm Label: Arm B (IC + cetuximab); Type: EXPERIMENTAL; Interventions: Biological: cetuximab, Drug: IC | Arm Label: ARM C (FOLFOX + cetuximab); Type: EXPERIMENTAL; Interventions: Biological: cetuximab, Drug: FOLFOX | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): ARM C (FOLFOX + cetuximab), Arm A (ECF + cetuximab), Arm B (IC + cetuximab) | Intervention Type: DRUG; Name: ECF; Assigned to Arm(s): Arm A (ECF + cetuximab) | Intervention Type: DRUG; Name: IC; Assigned to Arm(s): Arm B (IC + cetuximab) | Intervention Type: DRUG; Name: FOLFOX; Assigned to Arm(s): ARM C (FOLFOX + cetuximab)
C: Arm Label: Pembrolizumab; Type: EXPERIMENTAL; Interventions: Biological: pembrolizumab | Arm Label: Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel | Intervention Type: BIOLOGICAL; Name: pembrolizumab; Assigned to Arm(s): Pembrolizumab | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Paclitaxel
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olaparib, Drug: paclitaxel | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel, Drug: Placebo | Intervention Type: DRUG; Name: olaparib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rehabilitating Muscle After Intensive Care
Brief Summary: The study will examine the effect of amino acid supplements and enhanced physiotherapy on physical recovery following critical illness in intensive care.


Options:
A: Arm Label: ICU Recovery Manual & placebo supplement; Type: ACTIVE_COMPARATOR; Interventions: Other: Intensive Care Unit (ICU) Recovery Manual, Dietary Supplement: Placebo nutritional supplement | Arm Label: ICU recovery manual & amino acid (AA) supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Amino acid supplement, Other: Intensive Care Unit (ICU) Recovery Manual | Arm Label: PEPSE & placebo supplement; Type: EXPERIMENTAL; Interventions: Other: PEPSE, Other: Intensive Care Unit (ICU) Recovery Manual, Dietary Supplement: Placebo nutritional supplement | Arm Label: PEPSE & AA supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Amino acid supplement, Other: PEPSE, Other: Intensive Care Unit (ICU) Recovery Manual | Intervention Type: DIETARY_SUPPLEMENT; Name: Amino acid supplement; Assigned to Arm(s): ICU recovery manual & amino acid (AA) supplement, PEPSE & AA supplement | Intervention Type: OTHER; Name: PEPSE; Assigned to Arm(s): PEPSE & AA supplement, PEPSE & placebo supplement | Intervention Type: OTHER; Name: Intensive Care Unit (ICU) Recovery Manual; Assigned to Arm(s): ICU Recovery Manual & placebo supplement, ICU recovery manual & amino acid (AA) supplement, PEPSE & AA supplement, PEPSE & placebo supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo nutritional supplement; Assigned to Arm(s): ICU Recovery Manual & placebo supplement, PEPSE & placebo supplement
B: Arm Label: Exercise programme; Type: EXPERIMENTAL; Interventions: Other: Exercise Programme | Arm Label: Standard Care; Type: OTHER; Interventions: Other: Standard Care | Intervention Type: OTHER; Name: Exercise Programme; Assigned to Arm(s): Exercise programme | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): Standard Care
C: N/A
D: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Dapoxetine in Men With Premature Ejaculation and Concomitant Erectile Dysfunction Treated With a Phosphodiesterase-5 Inhibitor
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of dapoxetine compared to placebo in men with premature ejaculation and erectile dysfunction who are currently being treated with a phosphodiesterase-5 inhibitor (ie, sildenafil, vardenafil, or tadalafil) for erectile dysfunction.


Options:
A: Arm Label: Dapoxetine + PDE5I; Type: EXPERIMENTAL; Interventions: Drug: Dapoxetine, Drug: PDE5I (phosphodiesterase-5 inhibitor) | Arm Label: Placebo + PDE5I; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: PDE5I (phosphodiesterase-5 inhibitor) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + PDE5I | Intervention Type: DRUG; Name: Dapoxetine; Assigned to Arm(s): Dapoxetine + PDE5I | Intervention Type: DRUG; Name: PDE5I (phosphodiesterase-5 inhibitor); Assigned to Arm(s): Dapoxetine + PDE5I, Placebo + PDE5I
B: Intervention Type: DRUG; Name: dapoxetine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Dapoxetine; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Dapoxetine; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Influence of Local Biopsy of the Endometrium Prior to Controlled Ovarian Stimulation for IVF or ICSI Procedure on the Rates of Embryo Implantation, Clinical Pregnancy and Live Birth in ART
Brief Summary: In vitro fertilization (IVF) is the only available solution for many couples with various forms of infertility. The embryo implantation step in the IVF procedure is a complex multistage process and represents the majority of the causes of the IVF failure. Several approaches have been evaluated to improve implantation rates but none has demonstrated its superiority. However, endometrial receptivity is important for pregnancy and several studies suggest that local injury to the endometrium of IVF patients improves the rates of embryo implantation, clinical pregnancy and live birth.


Options:
A: Arm Label: Endometrial Injury; Type: ACTIVE_COMPARATOR; Interventions: Other: Endometrial Injury | Arm Label: Luteal Phase Support; Type: ACTIVE_COMPARATOR; Interventions: Drug: progesterone (Crinone® %8 vaginal progesterone gel) | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Endometrial Injury; Assigned to Arm(s): Endometrial Injury | Intervention Type: DRUG; Name: progesterone (Crinone® %8 vaginal progesterone gel); Assigned to Arm(s): Luteal Phase Support
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Endometrial biopsy | Intervention Type: OTHER; Name: Endometrial biopsy; Assigned to Arm(s): Intervention
C: Arm Label: group 1 : IVF with biopsy; Type: EXPERIMENTAL; Interventions: Procedure: biopsy | Arm Label: group 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: IVF | Intervention Type: PROCEDURE; Name: biopsy; Assigned to Arm(s): group 1 : IVF with biopsy | Intervention Type: PROCEDURE; Name: IVF; Assigned to Arm(s): group 2
D: Arm Label: GROUP A: intervention group; Type: EXPERIMENTAL; Interventions: Procedure: Endometrial scratch | Arm Label: GROUP B: no intervention group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Endometrial scratch; Assigned to Arm(s): GROUP A: intervention group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
Brief Summary: The purpose of this study is to determine if LY2189265 is effective and safe in reducing hemoglobin A1c (HbA1c), as compared to placebo (no medicine), or exenatide in participants with Type 2 Diabetes. The participants must also be taking metformin and pioglitazone.


Options:
A: Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Dapagliflozin; Type: EXPERIMENTAL; Interventions: Drug: Dapagliflozin 10 MG | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Dapagliflozin 10 MG; Assigned to Arm(s): Dapagliflozin
B: Arm Label: 1.5 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Metformin, Drug: Pioglitazone | Arm Label: 0.75 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Metformin, Drug: Pioglitazone | Arm Label: Exenatide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Exenatide, Drug: Metformin, Drug: Pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: LY2189265, Drug: Placebo, Drug: Metformin, Drug: Pioglitazone | Intervention Type: DRUG; Name: LY2189265; Assigned to Arm(s): 0.75 mg LY2189265, 1.5 mg LY2189265, Placebo | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): Exenatide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 0.75 mg LY2189265, 1.5 mg LY2189265, Exenatide, Placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): 0.75 mg LY2189265, 1.5 mg LY2189265, Exenatide, Placebo
C: Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glyburide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A
D: Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Empagliflozin; Type: ACTIVE_COMPARATOR; Interventions: Drug: empagliflozin | Intervention Type: DRUG; Name: empagliflozin; Assigned to Arm(s): Empagliflozin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Dietary Glycemic Index on Brain Function
Brief Summary: The investigators propose examine the effects of the dietary factor glycemic index (GI) on brain areas that control food intake and hunger. This knowledge could help design dietary approaches that decrease hunger, and thus promote new weight loss strategies.


Options:
A: Intervention Type: BEHAVIORAL; Name: Atkins diet (extremely low carbohydrate); Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Zone diet (low carbohydrate, high protein); Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Ornish diet (very low fat); Assigned to Arm(s): N/A
B: Arm Label: Low GI; Type: ACTIVE_COMPARATOR; Interventions: Other: Low GI | Arm Label: High GI; Type: EXPERIMENTAL; Interventions: Other: High GI | Intervention Type: OTHER; Name: Low GI; Assigned to Arm(s): Low GI | Intervention Type: OTHER; Name: High GI; Assigned to Arm(s): High GI
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Intervention Type: BEHAVIORAL; Name: High or low Glycemic Index and high or low Protein Diet; Assigned to Arm(s): 1, 2, 3, 4, 5
D: Arm Label: Experimental: Low-Carbohydrate Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Low-Carbohydrate Diet, Behavioral: Mobile App | Arm Label: Experimental: Low-Fat Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Low-Fat Diet, Behavioral: Mobile App | Intervention Type: BEHAVIORAL; Name: Low-Carbohydrate Diet; Assigned to Arm(s): Experimental: Low-Carbohydrate Diet | Intervention Type: BEHAVIORAL; Name: Low-Fat Diet; Assigned to Arm(s): Experimental: Low-Fat Diet | Intervention Type: BEHAVIORAL; Name: Mobile App; Assigned to Arm(s): Experimental: Low-Carbohydrate Diet, Experimental: Low-Fat Diet

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Does Therapeutic Education Improve Heart Failure Patient Quality of Life?
Brief Summary: Use lay language. Background: Heart failure is an increasingly frequent current pathology due to the population aging and the improvement of acute and chronic heart failure management. Heart failure patients have a poor quality of life because of their symptoms (asthenia, dyspnea...) and frequent hospitalizations. Heart failure is an expensive disease: 1.5 % of the health expenses, 85 % in hospital cost with 200 000 hospitalizations in France per year. Previous studies were multidisciplinary interventions and not realistic in a daily practice for a general practitioner. The aim of this project is to integrate therapeutic education for heart failure patients in a current practice. The patient becomes competent to manage his disease and to identify acute heart failure signs.

Main objective: Improve therapeutic education efficiency on life quality of heart failure patients in general practice.

Second objectives: Describe heart failure patient's hospitalizations.

Methods: Cluster randomized controlled clinical trial comparing intervention and control groups with a follow through for 19 months for each patient. A therapeutic education program will be proposed to the heart failure patients in primary care. The intervention group GP will follow a workshop concerning the therapeutic education concepts and the intervention.

Endpoints: Life quality evaluation (SF-36 and Minnesota scales) and number of hospitalizations of patients in each group.

Population: Heart failure patients in stages I, II, and III of NYHA in primary care. Cluster randomized surgeries in Auvergne (France).

Expected results: The therapeutic education allows the patients to improve their quality of life, to be able to detect their illness signs worsening in a early manner, and to contact their doctor if needed. This would limit the acute heart failure due to treatment adaptation or life habits.


Options:
A: Arm Label: behavioral intervention, counseling; Type: EXPERIMENTAL; Interventions: Behavioral: culturally tailored diabetes education | Arm Label: delyed intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: culturally tailored diabetes education; Assigned to Arm(s): behavioral intervention, counseling
B: Intervention Type: PROCEDURE; Name: Therapeutic education; Assigned to Arm(s): N/A
C: Arm Label: Post-discharge phone call; Type: N/A; Interventions: N/A | Arm Label: Usual care (no phone call); Type: N/A; Interventions: N/A
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Arm 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Control Study of Concerta and Strattera on the Improvement of Executive Function in Attention Deficit Hyperactivity Disorder Children
Brief Summary: The objective of this study is to compare the effect of Concerta (Osmotic Release Oral System Extended Release Methylphenidate HCL, OROS MPH) and Strattera (Atomoxetine) on the laboratory and ecological executive function in children with attention deficit hyperactivity disorder.


Options:
A: Intervention Type: BEHAVIORAL; Name: Psychosocial treatment; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Anti-ADHD medication; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Assessment-and-Referral; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: methylphenidate hydrochloride; Assigned to Arm(s): N/A
C: Arm Label: Aripirazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Quetiapine prolong; Type: EXPERIMENTAL; Interventions: Drug: Quetiapine | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripirazole | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Quetiapine prolong
D: Arm Label: OROS MPH; Type: EXPERIMENTAL; Interventions: Drug: OROS MPH | Arm Label: atomoxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atomoxetine | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: OROS MPH; Assigned to Arm(s): OROS MPH | Intervention Type: DRUG; Name: Atomoxetine; Assigned to Arm(s): atomoxetine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mindfulness-based Cognitive Therapy for Chronic Depression
Brief Summary: The propose of the study is to investigate the efficacy of Mindfulness-based Cognitive Therapy (MBCT, Segal, Williams, \& Teasdale, 2002) for patients suffering from Chronic Major Depression. The efficacy of MBCT will be compared with the Cognitive Behavioral Analysis System of Psychotherapy (McCullough, 2003), a treatment approach, which has proven it's efficacy yet, and with a treatment-as-usual condition (standard psychiatric outpatient care).


Options:
A: Arm Label: Mindfulness-based Cognitive Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-based Cognitive Therapy, Biological: Standard psychiatric care | Arm Label: CBASP; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: The Cognitive Behavioral Analysis System of Psychotherapy, Biological: Standard psychiatric care | Arm Label: Treatment-as-usual; Type: ACTIVE_COMPARATOR; Interventions: Biological: Standard psychiatric care | Intervention Type: BEHAVIORAL; Name: Mindfulness-based Cognitive Therapy; Assigned to Arm(s): Mindfulness-based Cognitive Therapy | Intervention Type: BEHAVIORAL; Name: The Cognitive Behavioral Analysis System of Psychotherapy; Assigned to Arm(s): CBASP | Intervention Type: BIOLOGICAL; Name: Standard psychiatric care; Assigned to Arm(s): CBASP, Mindfulness-based Cognitive Therapy, Treatment-as-usual
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Continuation phase cognitive therapy, Behavioral: Acute phase cognitive therapy | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Continuation phase pill placebo, Behavioral: Acute phase cognitive therapy | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Continuation phase fluoxetine, Behavioral: Acute phase cognitive therapy | Intervention Type: BEHAVIORAL; Name: Continuation phase cognitive therapy; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Continuation phase fluoxetine; Assigned to Arm(s): 3 | Intervention Type: OTHER; Name: Continuation phase pill placebo; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Acute phase cognitive therapy; Assigned to Arm(s): 1, 2, 3
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Continuation phase cognitive therapy, Behavioral: Acute phase cognitive therapy | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Continuation phase pill placebo, Behavioral: Acute phase cognitive therapy | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Continuation phase fluoxetine, Behavioral: Acute phase cognitive therapy | Intervention Type: BEHAVIORAL; Name: Continuation phase cognitive therapy; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Continuation phase fluoxetine; Assigned to Arm(s): 3 | Intervention Type: OTHER; Name: Continuation phase pill placebo; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Acute phase cognitive therapy; Assigned to Arm(s): 1, 2, 3
D: Intervention Type: DRUG; Name: Venlafaxine ER; Assigned to Arm(s): N/A

Answer: A